Cell line · CVCL_0479
PA-1
Cancer cell line, Homo sapiens. Ovarian mixed germ cell tumor. 37 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. PA-1. Cell lines, record CVCL_0479. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_0479
On this page
Cell line
As Cellosaurus gives it.
- Name
- PA-1
- Accession
- CVCL_0479
- RRID
- RRID:CVCL_0479
- Synonyms
- PA1, PA I, PAI
- Species
- Homo sapiens (Human)
- Sex
- Female
- Age at sampling
- 12Y
- Category
- Cancer cell line
- Diseases
- Ovarian mixed germ cell tumor (NCIt C8114); Mixed germ cell tumor (ORDO Orphanet_180234)
- Derived from
- Ascites (metastatic)
- Entry created
- 2012-04-04
- Entry updated
- 2025-04-10
Source Cellosaurus
Problems1
| Problem | Cellosaurus's note |
|---|---|
| Caution | TP53 mutation indicated to be at p.Asn239Asp (c.715A>G) in DOI=10.11418/jtca1981.16.3_173 and PubMed=9359923. |
Source Cellosaurus
Papers37
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Targeting CD24 Activates Macrophages to Reduce Tumor Burden in Preclinical Models of Solid Tumors. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Prognostic influence of small leucine-rich proteoglycans on serous ovarian cancer. | J Cancer Res Clin Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Moderate-Affinity Antibody-Drug Conjugate Targeting B7-H3 Exerts Potent Antitumor Efficacy. | Pharmaceuticals (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. | Cell | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Multifaceted role of POU5F1P1 in regulating its parental stem cell gene, POU5F1. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting Replication Fork Processing Synergizes with PARP Inhibition to Potentiate Lethality in Homologous Recombination Proficient Ovarian Cancers. | Adv Sci (Weinh) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Replenishing co-downregulated miR-100-5p and miR-125b-5p in malignant germ cell tumors causes growth inhibition through cell cycle disruption. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Metallo-protease Peptidase M84 from Bacillusaltitudinis induces ROS-dependent apoptosis in ovarian cancer cells by targeting PAR-1. | iScience | 2024 | Its Methods give the RRID and name the line | PubMed | |
| INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors. | Cancer Discov | 2024 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 37
See all 37 papersRelatives4
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | 222 | CVCL_1T15 | Has a recorded problem | Cell lines |
| Derived from it | CH1 [Human ovarian carcinoma] | CVCL_4992 | Has a recorded problem | Cell lines |
| Derived from it | PA-1/6TG-r | CVCL_3121 | Cell lines | |
| Derived from it | PA1 fat-1 | CVCL_E6ZI | Cell lines |
Cell banks9
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | CRL-1572 | ATCC | |
| BCRC | 60063 | BCRC | |
| CLS | 300402 | CLS | |
| ECACC | 90013101 | ECACC | |
| ICLC | HTL97002 | ICLC | |
| IZSLER | BS TCL 179 | Cellosaurus | |
| JCRB | JCRB9061 | JCRB | |
| RCB | RCB1946 | Discontinued | Cellosaurus |
| TKG | TKG 0573 | Discontinued | Cellosaurus |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0479
GET https://conductscience.org/api/cell-lines/v1/CVCL_0479/papers?page=2